Experimental lymphoma drug combo shows promise in early trial

NCT ID NCT05179603

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called SAR444245, alone or with pembrolizumab, in 14 people aged 12 and older with B cell lymphoma that came back or didn't respond to treatment. The goal was to see if the drug could shrink tumors. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSIC HODGKIN LYMPHOMA DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Investigational Site Number : 0320005

CABA, Buenos Aires, 1430, Argentina
Investigational Site Number : 1520001

Temuco, 4800827, Chile
Investigational Site Number : 1520002

Santiago, Reg Metropolitana de Santiago, 7500921, Chile
Investigational Site Number : 1520003

Santiago, Reg Metropolitana de Santiago, 7500653, Chile
Investigational Site Number : 1520004

Viña del Mar, Valparaiso, 2540488, Chile
Investigational Site Number : 7240001

L'Hospitalet de Llobregat, Barcelona [Barcelona], 08908, Spain
Investigational Site Number : 7240002

Barcelona, Barcelona [Barcelona], 08036, Spain
Investigational Site Number : 7240004

Madrid / Madrid, Madrid, Comunidad de, 28040, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.